Dr. Reddy’s had hoped to start moving beyond an FDA warning letter that lambasted three of its India plants for data integrity and other issues in 2015, but…

Sun Pharma’s Ranbaxy unit has started work on a manufacturing plant in Egypt, a project that got under way well before Sun bought Ranbaxy in 2015.

India’s Granules will do a significant expansion of its API bulk drug site in Vishakhapatnam, and is getting substantial help from the International Finance…

PRA and Takeda are building a Japan JV, Sun's quarterly profits dropped, ASLAN posted positive top-line phase 2 data for varlitinib.

The FDA has banned products from an Australian company's plant in Guangzhou, China, and cited it with “significant violations” of cGMP regulations saying…

The FDA has again slammed a Japanese drug company in a warning letter, this time for not doing enough to prevent contamination during aseptic filling.

Sun Pharma says it could be a few more quarters before it resolves FDA concerns over its key plant in Halol, a situation that continues to be a drag on its…

India’s Aurobindo has acquired four biosimilar products from a Swiss company and says it is building a manufacturing plant to support the production of those…

In a meeting with a host of Big Pharma execs last week, President Trump urged them to build plants and manufacture drugs in the U.S. Now a new U.S. plant has…

Pharma Asia